Intradiskal Injection of Methylene Blue for Discogenic Back Pain: A Meta-Analysis of Randomized Controlled Trials (2021)

Peer-Reviewed Study · Deng M, Huang H, Ma YG, et al. · January 21, 2021

Deng M et al., 2021-01-21: Meta-analysis of three randomized trials finding reduced pain scores at 3 and 6 months but no significant Oswestry improvement at 6 months.

Intradiskal injection of methylene blue can substantially decrease pain scores and improve function for discogenic back pain.

Deng M et al., 2021-01-21: Meta-analysis of three randomized trials finding reduced pain scores at 3 and 6 months but no significant Oswestry improvement at 6 months. Study type: systematic review and meta-analysis of RCTs. N=3 trials. Countries: China and Netherlands among the included trials. Intradiscal MB; doses as per included trials. Funding/conflicts: none declared. Comparator: placebo/control. Results: pain MD -0.71 at 3 months and -13.92 at 6 months; ODI no significant effect at 6 months (MD -11.76, p=0.28). Heterogeneity is the key issue: the pooled effect is driven by the Peng trial. Study type: review.